Allogene Therapeutics Inc Stock Ownership - Who owns Allogene Therapeutics?

Insider buying vs selling

Have Allogene Therapeutics Inc insiders been buying or selling?
David D. ChangPresident and CEO2023-03-1422,340$5.56
Eric Thomas SchmidtChief Financial Officer2023-03-1435,879$5.47
Alison MooreChief Technical Officer2023-03-148,351$5.51
Veer BhavnagriGeneral Counsel2023-03-1423,628$5.67
Veer BhavnagriGeneral Counsel2023-02-133,000$6.85
Veer BhavnagriGeneral Counsel2023-01-173,000$7.04
Veer BhavnagriGeneral Counsel2022-12-155,602$7.53
Rafael AmadoEVP of RD2022-10-078,464$11.83
Rafael AmadoEVP of R&D2022-10-038,968$11.06
Owen N. WitteDirector2022-08-125,000$17.25

1 of 2

ALLO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALLO insiders and whales buy or sell their stock.

ALLO Shareholders

What type of owners hold Allogene Therapeutics Inc stock?
Pfizer Inc15.11%22,032,040$128.67MInsider
Tpg GP A LLC12.83%18,716,306$109.30MInsider
Tpg Group Holdings Sbs Advisors Inc12.83%18,716,306$109.30MInsider
Tpg GP A LLC12.83%18,716,306$109.30MInstitution
Blackrock Inc6.26%9,123,092$53.28MInstitution
State Street Corp5.63%8,211,074$47.95MInstitution
Vanguard Group Inc5.01%7,305,336$42.66MInstitution
Arie Belldegrun4.36%6,365,006$37.17MInsider
Price T Rowe Associates Inc4.34%6,330,304$36.97MInstitution
Primecap Management Co3.96%5,768,986$33.69MInstitution

1 of 3

ALLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALLO60.01%39.99%Net SellingNet Selling
ARDX33.77%66.23%Net BuyingNet Selling
RNA82.27%17.73%Net BuyingNet Buying

Allogene Therapeutics Stock Ownership FAQ

Who owns Allogene Therapeutics?

Allogene Therapeutics (NASDAQ: ALLO) is owned by 79.51% institutional shareholders, 52.99% Allogene Therapeutics insiders, and 0.00% retail investors. Pfizer Inc is the largest individual Allogene Therapeutics shareholder, owning 22.03M shares representing 15.11% of the company. Pfizer Inc's Allogene Therapeutics shares are currently valued at $127.79M.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.